SCHEMBL7248694

SCHEMBL7248694

C=CC[C@H](C(N)=O)[C@@H](CC(C)C)C(=O)N[C@H]1CC=CC2CN(Cc3ccccc3)CCN2C1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NOTCH1 P46531 2/20 0.43
▸ RBPJ Q06330 2/20 0.43
▸ APP P05067 10/20 0.42
▸ MMP2 P08253 7/20 0.40
▸ MMP3 P08254 7/20 0.40
▸ MMP7 P09237 6/20 0.40
▸ PSEN1 P49768 1/20 0.40
▸ PSEN2 P49810 1/20 0.40
▸ APH1B Q8WW43 1/20 0.40
▸ NCSTN Q92542 1/20 0.40
▸ APH1A Q96BI3 1/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ MMP1 P03956 5/20 0.39
▸ MMP8 P22894 2/20 0.38
▸ ADAM17 P78536 1/20 0.38
▸ MMP9 P14780 1/20 0.38
▸ MMP12 P39900 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ MMP14 P50281 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7248308 0.94 APP (0.43) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL7251051 0.94 APP (0.43) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL7246639 0.77 FPR2 (0.43) —
SCHEMBL4490715 0.76 APP (0.68) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL4499276 0.73 NOTCH1 (0.50) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL4485658 0.73 APP (0.58) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL7247698 0.72 APP (0.48) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL4479182 0.69 NOTCH1 (0.52) NOTCH1RBPJAPPMMP2MMP3
SCHEMBL13920941 0.69 APP (0.65) NOTCH1RBPJAPPMMP2MMP7
SCHEMBL4471344 0.69 NOTCH1 (0.47) NOTCH1RBPJAPPMMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020055501-A1 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 — — US claimed
US-6525044-B2 Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. BRISTOL-MYERS SQUIBB COMPANY 2003-02-25 — — US disclosed
EP-1261610-A2 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-12-04 — — EP disclosed
US-20020055501-A1 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 — — US disclosed
WO-2001060826-A2 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055501-A1 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production APP, APH1A, APH1B NOTCH1 383/4885RBPJ 2054/4885APP 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback